Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

SANOFI : Former Sanofi employees convicted of bribery in Germany

share with twitter share with LinkedIn share with facebook
share via e-mail
03/03/2014 | 07:24pm CEST

A German court convicted two former employees of Sanofi-Aventis on bribery charges 10 months ago and imposed a fine on the French drugmaker last year, prosecutors said on Monday following a newspaper report.

News of the 28 million euro ($39 million) fine coincides with heightened scrutiny of Big Pharma's sales practices after a bribery scandal in China hit business there last year.

Further investigations are ongoing, a spokesman for prosecutors in the northern German town of Verden said, confirming a report by German daily newspaper Frankfurter Allgemeine Zeitung, but they declined to say whether these were related to Sanofi or to its employees.

The spokesman said an investigation of the former Sanofi employees found that they had made illicit payments to a consultancy advising one of the drugmaker's clients between 2007 and 2010 to win more orders from the client, a pharmaceuticals dealer.

"Sanofi was unfairly given preference because of this," he said.

He declined to provide details on who the client was or which markets it operated in. He also did not name the former Sanofi employees or the consultant.

A court in the town of Winsen handed the two former employees of Sanofi suspended sentences for bribery in business transactions in May 2013, the spokesman said. They both worked with Sanofi's sales force and were not senior managers.

The Winsen court also ordered that punishment be meted out to the owner of the consultancy, but that judgment was not yet final due to a pending complaint against the ruling.

The bribery investigation has not come to light until now because the suspects were sentenced via a simplified legal process that under German law allows courts to try some crimes without a courtroom trial.

The court's ruling also resulted in a 28 million euro fine for Sanofi. A spokeswoman for Sanofi-Aventis Deutschland GmbH confirmed the company had to pay that sum in connection with the case against the two former employees.

"For Sanofi the matter is closed," the spokeswoman said, referring to the Winsen court's rulings. She added the company had cooperated with authorities during the investigation and had since further tightened its compliance system.

Sanofi acquired Aventis in 2004, creating Sanofi-Aventis. In 2011, the company simplified its name to Sanofi.

(Reporting by Maria Sheahan and Frank Siebelt; Additional reporting by Natalie Huet in Paris; Writing by Marilyn Gerlach; editing by Mike Collett-White)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
07/23 SANOFI : Judicial Panel on Multidistrict Litigation Issues Order on Taxotere
07/22 SANOFI : Regeneron Receive Positive CHMP Opinion for Dupixent (dupilumab) to Tre..
07/22 SANOFI : MSDs Lantus biosimilar given conditional FDA approval
07/22 SANOFI INDIA : Competition Commission of India rejects unfair business practices..
07/21 SANOFI : Annual fundraiser honors nonprofits
07/21 SANOFI : Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupil..
07/21 SANOFI : and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) t..
07/20 SANOFI : Disclosure of trading in own shares
07/20 AUROBINDO PHARMA : Gets nod to sell kidney drug
07/20 SANOFI : 2017-2018 Flu Vaccine on Its Way to US
More news
News from SeekingAlpha
07/21 Sirukumab's Panel And U.S. Decision For Medicines Company
07/21 European advisory group backs approval of 11 new meds
07/20 FDA tentatively OKs Merck's biologic basal insulin
07/20 Ablynx and Sanofi team up to develop Nanobody-based therapeutics for inflamma..
Financials (€)
Sales 2017 36 571 M
EBIT 2017 9 546 M
Net income 2017 7 948 M
Debt 2017 4 763 M
Yield 2017 3,74%
P/E ratio 2017 12,97
P/E ratio 2018 16,81
EV / Sales 2017 2,94x
EV / Sales 2018 2,82x
Capitalization 102 777 M
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Technical analysis trends SANOFI
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 86,1 €
Spread / Average Target 5,7%
EPS Revisions
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias A. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI6.01%119 827
JOHNSON & JOHNSON17.45%364 503
ROCHE HOLDING LTD.4.90%221 492
NOVARTIS8.37%220 936
PFIZER3.08%199 378